The BRAVE project* will develop infrastructure for post-authorisation vaccine safety surveillance in low- and middle-income countries (LMICs) and identify the rates of potential adverse events of special interest (AESI) before the introduction of new vaccines. Surveillance of the rates of the same AESI in a similar population after a vaccine is introduced and comparison of these ‘observed rates’ with the ‘background rates’ may identify potential vaccine safety signals that require further investigation.

The Global Vaccine Data Network (GVDN) and CEPI are partnering with institutions in five African countries, Uhe University of the Witwatersrand in South Africa, Navrongo Health Research Center in Ghana, International Foundation Against Infectious Diseases in Nigeria, Eagle Research Center in Rwanda, and Health Research Operations Kenya (operating as KEMRI-Wellcome Trust Research Programme) in Kenya to do this work.

CEPI, the Coalition for Epidemic Preparedness Innovations, is supporting the development of several vaccines specifically targeting diseases affecting LMICs, including Lassa fever, Rift Valley fever, dengue and Chikungunya fever, and Nipah virus.

^{*This project is funded by CEPI.}